Navigation Links
Phase 2b Study of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment Ended (SVR12)
Date:4/19/2012

oral HCV NS3/4A protease inhibitor that has shown the potential to improve cure rates as compared to PegIFN/RBV therapy alone, has completed clinical trials through Phase 2b (SILEN-C studies). A multi-study Phase 3 trial program currently is underway to evaluate BI 201335 combined with PegIFN/RBV in treatment-naive, treatment-experienced and HIV co-infected patients with chronic genotype-1 HCV.

BI 207127, an NS5B RNA-dependent polymerase inhibitor that has shown the potential to eliminate interferon from HCV treatment when combined with BI 201335 and RBV, is currently being investigated in Phase 2 trials in interferon-sparing regimens.

About Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies.  Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible.  Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringeru
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
2. Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer
3. Encouraging Phase III Study Results Show PET Imaging with Florbetaben Reliably Detects Beta-Amyloid in the Brain
4. QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR
5. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
6. UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
7. Bionovos Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™
8. Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia
9. iBio Announces Successful Completion of H1N1 Influenza Vaccine Phase 1 Clinical Trial
10. Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
11. Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiologys Annual Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... MILPITAS, Calif. , July 10, 2014 ... a leader in advanced memory and analog IC solutions, ... call on Thursday, July 24, 2014, at 7:00 a.m. ... Company,s financial results for the fiscal 2014 third quarter ... conference call via telephone, dial 1-888-556-4997 before 6:50 a.m. ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical ... today announced it has entered into an agreement with ... operates as EMD Serono in the United ... to collaborate with Merck KGaA,s biopharmaceutical division on the ... an undisclosed target using Ventana,s proprietary diagnostic assays. In ...
(Date:1/15/2014)... 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced sales ... compared to sales of $2,202,000 for the prior year period, ... has also shown growth over the preceding quarter,s sales, continuing ... fiscal year. Markets that experienced sales increases over the prior ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Volcano Corporation (Nasdaq: VOLC ) announced today the completion of the first ... performed in seven centers within the United States . Commercial launch of Eagle ... , , ... , , ...
... , SAN DIEGO , May 20 ... announced today that the U.S. Patent and Trademark Office has ... microfluidic device. U.S. patent #7,695,956 entitled "Device for Cell Separation ... to isolate cells from a bodily fluid using a flow ...
Cached Medicine Technology:Physicians Cite Positive First Clinical Experience with Volcano's Eagle Eye® Platinum Digital IVUS Catheter 2Physicians Cite Positive First Clinical Experience with Volcano's Eagle Eye® Platinum Digital IVUS Catheter 3Physicians Cite Positive First Clinical Experience with Volcano's Eagle Eye® Platinum Digital IVUS Catheter 4Biocept, Inc. Announces Issuance of Patent for its Microfluidic Technology 2
(Date:7/12/2014)... 2014 “Critical Care Therapeutics in ... Late-Stage Four-Factor PCCs and Recombinant Products to Drive ... care market in the US, UK, France, Germany, ... an estimation of market size for 2013, along ... care indications that are being treated using the ...
(Date:7/12/2014)... July 12, 2014 Utah Valley Entrepreneurial ... startups, with awards being bestowed to companies in revenue, ... outstanding entrepreneur community with recognition for new ideas as ... with incoming revenue. , 25 Under 5 highlights outstanding ... that are under 5 years old. Award recipients were ...
(Date:7/12/2014)... Texas (PRWEB) July 12, 2014 ... Breastfeeding Made Simple as a valuable new resource for ... roughly two-thirds of American women work away from their ... sources touting the benefits of breastfeeding, but often feel ... to nurse their babies. With its evidence-based insights, and ...
(Date:7/12/2014)... CA (PRWEB) July 12, 2014 ... power score of 4.1 out of 5. This ... that have been underpinning buyer negotiation power over ... procurement analyst Anna Son, “during the period, surging ... rising costs associated with new product development, have ...
(Date:7/12/2014)... Ladies, it doesn't matter what your budget is, ... looking for an affordable gown can visit Discount-Dress.com ... get their dream items. Recently, the company has announced its ... Along with that, it is also providing great discounts for ... the deadline of this promotion is July 29, 2014. ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2
... YORK (June 15, 2011) -- Ever since the Institute of ... 1999, significant attention has been paid to improving patient safety ... events, including major injury and even death, occur in private ... study -- the first of its kind -- researchers at ...
... , TUESDAY, June 14 (HealthDay News) -- Patients ... if they have elevated levels of a certain hormone, a ... (FGF-23) regulates phosphorus metabolism. It was known that levels of ... of the hormone are associated with increased risk of death ...
... where open space is plentiful and there is often ... rural elders are far more likely to be overweight ... suburban counterparts, according to a new policy brief from ... All three conditions are risk factors for heart ...
... growth is blocked by drugs targeting that path, the malignancy ... around the roadblock. In a study at UCLA,s Jonsson ... of prostate cancer was treated with conventional hormone ablation therapy ... growth of the tumor the cancer was able to ...
... Day this Sunday is a chance to recognize dads for putting ... up on the way to adulthood. But a new study ... dad,s job as a role model actually is. The study, ... and Environmentally Controlled Sibling Study," is due to be published in ...
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, June ... they might also sleep better, according to researchers who say ... sleeptime, may help treat insomnia. Previous research has shown ... have a higher brain metabolism in the frontal lobes, which ...
Cached Medicine News:Health News:JAMA study points to patient safety risks outside hospital walls 2Health News:JAMA study points to patient safety risks outside hospital walls 3Health News:Hormone Linked to Death Risk in Those With Early Kidney Disease 2Health News:Out of reach? Rural elders have highest rates of obesity, diabetes, heart disease 2Health News:Prostate cancer gets around hormone therapy by activating a survival cell signaling pathway 2Health News:Prostate cancer gets around hormone therapy by activating a survival cell signaling pathway 3Health News:Note to dads: Good parenting makes a difference 2Health News:Sleeptime Head-Cooling Cap Eases Insomnia, Study Finds 2Health News:Sleeptime Head-Cooling Cap Eases Insomnia, Study Finds 3
The three point staple, used for valgus tibial osteotomy, is easy and quick to fit, with a compact size compared with other existing systems....
... design of the osteotomy staples is quite similar to ... are the inner position of the anti recoil contours ... staples). There are 3 kinds of staples: ... and the staples can have 3 different widths: 20mm, ...
A new generation of ORTHOMED S.A. fixation staples, manufactured from cobalt-chromium alloy: tried and test strength and tolerance...
... Sterile Barium Sulfate USP is specifically ... consistent imaging capabilities for todays medical ... minimally invasive surgery. Comprised of a ... even diffusion of sterile barium, resulting ...
Medicine Products: